NKTR

Nektar Therapeutics

70.93

USD

NKTR Earnings Reports

Positive Surprise Ratio

NKTR beat 33 of 41 last estimates.

80%

Next Report

Date of Next Report

May 06, 2026

Estimate for Q1 26 (Revenue/ EPS)

$10.87M

-$1.81

Implied change from Q4 25 (Revenue/ EPS)

-50.17%

+1.69%

Implied change from Q1 25 (Revenue/ EPS)

+4.02%

-49.72%

Nektar Therapeutics earnings per share and revenue

On Mar 12, 2026, NKTR reported earnings of -1.78 USD per share (EPS) for Q4 25, beating the estimate of -2.52 USD, resulting in a 29.47% surprise. Revenue reached 21.81 million, compared to an expected 10.61 million, with a 105.50% difference. The market reacted with a +4.11% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 8 analysts forecast an EPS of -1.81 USD, with revenue projected to reach 10.87 million USD, implying an increase of 1.69% EPS, and decrease of -50.17% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Theravance Biopharma, Inc.

Report Date

Mar 19, 2026 For Q4 25

Estimate

$1.24

Actual

$0.21

Surprise

-83.12%

Context Therapeutics Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.14

Surprise

-29.39%

Avalo Therapeutics, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$1.49

Actual

-$1.12

Surprise

+24.33%

Journey Medical Corporation Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.04

Surprise

+31.86%

Surrozen, Inc. Common

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$1.21

Actual

Surprise

Achieve Life Sciences, Inc.

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.12%

Pyxis Oncology, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.28

Surprise

+15.55%

Fractyl Health, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

$0.15

Surprise

+181.70%

NRX Pharmaceuticals, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.01

Surprise

-361.54%

electroCore, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.41

Actual

-$0.34

Surprise

+18.15%

FAQ

What were Nektar Therapeutics's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Nektar Therapeutics reported EPS of -$1.78, beating estimates by 29.47%, and revenue of $21.81M, 105.5% above expectations.

How did the market react to Nektar Therapeutics's Q4 2025 earnings?

The stock price moved up 4.11%, changed from $70.36 before the earnings release to $73.25 the day after.

When is Nektar Therapeutics expected to report next?

The next earning report is scheduled for May 06, 2026.

What are the forecasts for Nektar Therapeutics's next earnings report?

Based on 8 analysts, Nektar Therapeutics is expected to report EPS of -$1.81 and revenue of $10.87M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.